Sagittarius Life Science Corp carries a market capitalization of 3.53B, placing it among publicly traded companies globally. Its enterprise value stands at 1.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.53B |
| Enterprise Value | 1.73B |
Sagittarius Life Science Corp currently has 67.55M shares outstanding.
| Shares Outstanding | 67.55M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
The price-to-sales ratio is 7.31, and the price-to-book ratio stands at 4.04.
| PE Ratio | N/A |
| PS Ratio | 7.31 |
| PB Ratio | 4.04 |
| P/TBV Ratio | 2.42 |
| P/FCF Ratio | -70.99 |
| P/OCF Ratio | -70.19 |
| EV / Sales | 5.00 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Sagittarius Life Science Corp maintains a current ratio of 31.84, meaning it holds 31.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.04, indicating conservative leverage, while an interest coverage ratio of -860.35 demonstrates limited ability to service its debt obligations.
| Current Ratio | 31.84 |
| Quick Ratio | 30.92 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -860.35 |
| Return on Equity (ROE) | -10.98 |
| Return on Assets (ROA) | -6.23 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 14.41 |
Sagittarius Life Science Corp's stock has gained approximately 3.16206% over the past 52 weeks. The 50-day moving average sits at 54.28, while the 200-day moving average is 52.12.
| Beta (5Y) | N/A |
| 52-Week Price Change | 3.16206% |
| 50-Day Moving Average | 54.28 |
| 200-Day Moving Average | 52.12 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Sagittarius Life Science Corp generated 346.08M in revenue and converted that into -49.56M in net income, yielding earnings per share of -1.01. EBITDA reached -58.50M, while operating income came in at -58.50M.
| Revenue | 346.08M |
| Gross Profit | 57.71M |
| Operating Income | -58.50M |
| Pretax Income | -49.87M |
| Net Income | -49.56M |
| EBITDA | -58.50M |
| EBIT | -58.50M |
| Earnings Per Share (EPS) | -1.01 |
Sagittarius Life Science Corp holds 803.55M in cash and equivalents against 385,000.00 in total debt, resulting in a net debt position of -151.55M. Total book value stands at 625.89M, with working capital of 801.46M providing operational flexibility.
| Cash & Cash Equivalents | 803.55M |
| Total Debt | 385,000.00 |
| Net Debt | -151.55M |
| Equity (Book Value) | 625.89M |
| Book Value Per Share | 12.69 |
| Working Capital | 801.46M |
Sagittarius Life Science Corp produced -36.05M in operating cash flow over the past twelve months. After subtracting -404,000.00 in capital expenditures, free cash flow totaled -36.45M - equivalent to -0.74 per share.
| Operating Cash Flow | -36.05M |
| Capital Expenditures | -404,000.00 |
| Free Cash Flow | -36.45M |
| FCF Per Share | -0.74 |
Sagittarius Life Science Corp operates with a gross margin of 16.68, reflecting its pricing power and cost economics. The operating margin of -16.90 and net profit margin of -14.32 provide insight into operational efficiency.
| Gross Margin | 16.68 |
| Operating Margin | -16.90 |
| Pretax Margin | -14.41 |
| Profit Margin | -14.32 |
| EBITDA Margin | -16.90 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -26.20 |
| FCF Yield | -1.41 |
Sagittarius Life Science Corp's most recent stock split took place on August 16, 2016 with a 1000:1057 split ratio.
| Last Split Date | 8/16/2016 |
| Split Ratio | 1000:1057 |
Sagittarius Life Science Corp posts an Altman Z-Score of 57.39, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 57.39 |